EGFR Mutation-positive Inoperable or Reccrent NSCLC
1 clinical trials · Condition
◉ Watch EGFR Mutation-positive Inoperable or Reccrent NSCLC
| Record | Firm | Date |
|---|---|---|
| Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice) (NCT04155541) | Pfizer | 2020-01-24 |
Track EGFR Mutation-positive Inoperable or Reccrent NSCLC automatically
Every clearance here is in the API, with alerts when new ones post.